Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
CaaS Capital Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
CaaS Capital Management

CaaS Capital Management

Operating

CaaS Capital Management: A NYC-based global investment firm, specializing in equity markets and capital raising.

Location
New York City, NY, US
Founded
2019
Firm
Compare
Portfolio
Employees
Website

CaaS Capital Management is a New York City-based global investment firm specializing in equity capital markets and liquidity provision. The firm actively participates in both private and public markets, focusing on Series B, Series C, Post-IPO Equity, and Private Equity rounds. CaaS Capital Management aims to assist businesses in achieving their capital-raising goals while adhering to meticulous risk controls and diversification strategies.

Notable portfolio companies include 2seventy bio, HotSpot Therapeutics, Rapid Micro Biosystems, Solid Biosciences, StrideBio, Umoja Biopharma, and Werewolf Therapeutics. The firm is a single-family office that emphasizes cultivating mutually beneficial relationships among stakeholders and effecting positive change through its investments. CaaS Capital Management leverages its extensive expertise to provide value-added services to its portfolio companies, ensuring sustainable growth and success.

CaaS Capital Management - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments7
Current Portfolio Count7
Total Portfolio Exits0

Top Investment Stages

Series B3 (42.9%)
Post Ipo Equity2 (28.6%)
Private Equity1 (14.3%)
Series C1 (14.3%)

Stage Mix

Series B 43%Post Ipo Equity 29%Private Equity 14%Series C 14%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Solid Biosciences logo

Solid Biosciences

2seventy bio logo

2seventy bio

HotSpot Therapeutics logo

HotSpot Therapeutics

Umoja Biopharma logo

Umoja Biopharma

Rapid Micro Biosystems logo

Rapid Micro Biosystems

StrideBio logo

StrideBio

Werewolf Therapeutics logo

Werewolf Therapeutics

CaaS Capital Management - Similar Investment Firms

Cape Capital logo

Cape Capital

capecapital.com

CS Capital logo

CS Capital

cscapital.cn

Ceas Investments logo

Ceas Investments

CSA Partners logo

CSA Partners

Caffeinated Capital logo

Caffeinated Capital

Crowdfund Capital Advisors logo

Crowdfund Capital Advisors

Brio Capital Management logo

Brio Capital Management

Invicta Management logo

Invicta Management

Casdin Capital logo

Casdin Capital

casdincapital.com

CAM Capital logo

CAM Capital

camcapital.com

Ra Capital Management logo

Ra Capital Management

racap.com

Nexus Capital Management logo

Nexus Capital Management

nexuslp.com

Mirae Asset Capital Life Science logo

Mirae Asset Capital Life Science

CAZ Investments logo

CAZ Investments

cazinvestments.com

Thirdbase Capital logo

Thirdbase Capital

thirdbasecap.com

CaaS Capital Management - Classification

Also Known As
  • CaaS Capital Management LP
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 2 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
SIC
  • 6000Depository Institutions